|Drug class||α-glucosidase inhibitor|
|Main uses||Type 2 diabetes|
|Side effects||Diarrhea, abdominal pain, increased intestinal gas|
|By mouth (tablets)|
|Typical dose||300 mg TID|
|Protein binding||Negligible (<4.0%)|
|Elimination half-life||2 hours|
|Chemical and physical data|
|Molar mass||207.226 g·mol−1|
|3D model (JSmol)|
|Melting point||114 °C (237 °F)|
Miglitol, sold under the brand name Glycet, is a medication used to treat type 2 diabetes. It is taken by mouth. It is used together with diet and exercise.
Common side effects include diarrhea, abdominal pain, and increased intestinal gas. Well there is no evidence of harm in pregnancy, such use has not been well studied. It is an α-glucosidase inhibitor which decreases the break down complex carbohydrates into glucose.
Miglitol was approved for medical use in the United States in 1996. It is available as a generic medication. In the United States it costs about 24 USD per month as of 2021.
It is taken at a dose of 300 mg three times per day.
Miglitol, and other structurally-related iminosugars, inhibit glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Miglitol Monograph for Professionals". Drugs.com. Archived from the original on 14 August 2020. Retrieved 18 November 2021.
- ↑ "Miglitol (Glyset) Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2020. Retrieved 18 November 2021.
- ↑ 3.0 3.1 "Miglitol Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 18 November 2021.
- ↑ "Glyset (miglitol) tablets label - Accessdata FDA" (PDF). Drugs@FDA. U.S. Food and Drug Administration. August 2012. Archived (PDF) from the original on 1 November 2018. Retrieved 13 April 2013.
- Pages using duplicate arguments in template calls
- Articles with hatnote templates targeting a nonexistent page
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Alpha-glucosidase inhibitors
- All stub articles
- Gastrointestinal system drug stubs